The asymmetrical ROS–METTL3–ESR1 axis in paraspinal muscle progenitor cells determines the progression of adolescent idiopathic scoliosis

Read full text
Authors: Bo Li, Amila Kuati, Wenyuan Sui, Jinkui Cai, Tianyuan Zhang, Yaolong Deng, Jie Yang, Xingzuan Lin, Xiexiang Shao
Cited by: 1
References: 53

Abstract

Abstract Adolescent idiopathic scoliosis (AIS) is the most common spinal deformity, yet its precise etiology remains elusive. Our previous research highlighted the pivotal role of the asymmetrical ESR1 expression of paraspinal muscle stem/progenitor cells in the progression of AIS. However, the widespread distribution of ESR1 in various organs and tissues limits its safety and efficacy as a therapeutic target. Therefore, it is imperative to investigate the regulatory mechanisms governing the asymmetric ESR1 expression in paraspinal muscle stem/progenitor cells to identify safer and more effective treatment strategies for AIS. Here we discovered elevated levels of reactive oxygen species (ROS) in the concave paraspinal muscles of patients with AIS. The increased ROS decreased the expression of m 6 A methyltransferase METTL3, which further diminished the expression of ESR1 in an m 6 A-dependent manner in concave paraspinal muscle stem/progenitor cells. Thus, the asymmetrical ROS–METTL3–ESR1 axis in paraspinal muscle stem/progenitor cells plays a crucial role in the progression of AIS. Unilateral oxidative stress is one of the causes of AIS through the asymmetrical ROS–METTL3–ESR1 axis in paraspinal muscle stem cells. Furthermore, the antioxidant and methyl donor betaine effectively mitigated the differentiation defects of concave muscle stem/progenitor cells and alleviated the progression of scoliosis through targeting the ROS–METTL3–ESR1 axis. Reducing ROS and increasing METTL3 expression in paraspinal muscle stem cells on the concave side may represent a novel therapeutic strategy for AIS.

Fields of Study & Subjects

Scoliosis diagnosis and treatment Spine and Intervertebral Disc Pathology Pregnancy-related medical research

Publication details

Journal / source
Experimental & Molecular Medicine
Publisher
Springer Science and Business Media LLC
Volume
58
Issue
3
Pages
725–738
Publication date
5 March 2026
Language
EN